NovoLog (insulin aspart) / Novo Nordisk - LARVOL DELTA

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (clinicaltrials.gov) - P=N/A | N=218 | Completed | Sponsor: Beijing Hospital | Not yet recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Aug 2025 | Trial primary completion date: Dec 2023 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. (clinicaltrials.gov) - P4 | N=76 | Completed | Sponsor: Medical University of Warsaw | Not yet recruiting ➔ Completed | Trial completion date: Aug 2023 ➔ Dec 2024

Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

In brief: Kirsty - an insulin aspart interchangeable with NovoLog. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

NIVOLUMAB-INDUCED DKA IN A PREVIOUS NONDIABETIC (CHEST 2025) - "Patient subsequently was discharged home with Lantus and NovoLog. With the increasing use of Checkpoint inhibitors in malignancies, practitioners should be aware of potentially serious complications including DKA and worsening glycemic control. Monitoring blood glucose and HbA1C levels before and after initiation of an immune checkpoint inhibitor should be discussed with patients prior to initiating therapy, in order to help monitor for potentially serious complications."

Hypertension • Melanoma • Metabolic Disorders • Solid Tumor • Type 2 Diabetes Mellitus

HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - P=N/A | N=150 | Active, not recruiting | Sponsor: Weill Cornell Medical College in Qatar | Trial completion date: Oct 2024 ➔ Oct 2026

Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Mark D. DeBoer, MD, MSc., MCR | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=260 | Recruiting | Sponsor: Emory University | Trial completion date: Jul 2025 ➔ May 2026 | Trial primary completion date: Jul 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders

Preserved C-peptide Five Years After LADA Diagnosis: Focus On Prandial Glycaemic Control (ENDO 2025) - "She was started on sc Novorapid 3-6 units 15 mins premeal at 1 unit to 10-gram carbs, and PO linagliptin 5 mg om. Empagliflozin and metformin were discontinued...However, the use of DPP4-inhibitors has been found useful. CONCLUSION RCTs utilizing C-peptide and CGM to inform the best regimens of insulin and/or OHA treatment for C-peptide preservation in LADA patients are needed."

Diabetes • Hypoglycemia • Immunology • Metabolic Disorders

Navigating the Uncertainty: Atypical Diabetes Mellitus with Negative Biomarkers and Complex Management (ENDO 2025) - "He was discharged with insulin (Lantus 8 units and Novolog 2 units TID) and metformin (METF) 1000 mg BID.Two weeks later when he was evaluated in clinic he was only taking METF with small doses of short-acting insulin, as needed...Patient was trialed with acarbose with no effect on BG, then a dipeptidyl peptidase-4 (DDP-4) inhibitor... This case highlights the complexity involved in diagnosing and managing atypical forms of DM, including LADA, monogenic, and ketosis-prone DM. It is a spectrum, which may present with features of both type 1 and type 2 DM but lacks definitive biomarkers. Clinicians should consider the atypical forms in adult patients with new-onset diabetes and atypical presentations, especially when there is an absence of typical autoimmune markers."

Biomarker • Diabetes • Diabetic Retinopathy • Fatigue • Hypoglycemia • Immunology • Metabolic Disorders • Renal Disease • Retinal Disorders • Type 1 Diabetes Mellitus

Unraveling The Diagnosis: A Case Of HNF1A-MODY Misclassified As Type 1 Diabetes (ENDO 2025) - "He was overweight at diagnosis, started on metformin, then transitioned to insulin due to poor glycemic control...His regimen was adjusted to include Lantus, Novolog, and Trulicity, improving HbA1c to 7.9%...He was transitioned to glipizide, pioglitazone, and Trulicity, achieving an HbA1c of 6.9%.This case emphasizes the need to reassess diabetes diagnoses in patients with poor control and strong family histories...This case emphasizes the need to reassess diabetes diagnoses in patients with poor control and strong family histories. Misclassification as T1DM led to years of ineffective insulin therapy. A comprehensive evaluation, including C-peptide, antibody testing, and genetic analysis, enabled correct diagnosis and optimized therapy."

Clinical • Late-breaking abstract • Diabetes • Endocrine Disorders • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • HNF1A

Assessing Biosimilarity of Insulin Aspart Injection and NovoRapid® Through Pharmacokinetic and Pharmacodynamic Comparisons in Healthy Volunteers: A Double-Blind, Randomized, Crossover Study. (PubMed, Eur J Pharmacol) - "Wockhardt's Insulin Aspart Injection demonstrated bioequivalence to NovoRapid® confirming comparable efficacy and safety."

Journal • PK/PD data

In brief: Merilog - a NovoLog biosimilar. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Comparing Medicare Maximum Fair Prices with Other Drug Prices in Other Countries (ISPOR 2025) - " The comparison showed that the costs of the 10 drugs included in the Part D negotiations (Januvia, Fiasp/NovoLog/NovoRapid insulin products, Farxiga/Forxiga, Enbrel, Jardiance, Xarelto, Eliquis, Entresto, Stelara, and Imbruvica) were still lower in other countries even after price negotiations. Despite substantial discounts provided by Medicare price negotiations, US maximum fair prices remain generally higher than prices applied in other countries with high healthcare spending per capita. A limitation of the analysis is the approximation of monthly drug costs without utilization data."

Medicare • Reimbursement • US reimbursement

Post-surgical biliary pancreatitis and GAD positive diabetes: a rare case of Type 3c DM with Autoimmune features (ESPE-ESE 2025) - "Pain control due to opioid intolerance (hallucinations on morphine and nausea with oxycodone) required PCA fentanyl 20 mcg bolus, paracetamol, and diclofenac supplement...The patient was managed with basal-bolus insulin (Lantus 28 units nightly, Novorapid 8-14 units per meal ) and sliding scale correction for blood glucose 10 mmol/L. The patient was discharged with a management plan of Creon 250,000 units and Humalog 12-20 units with a meal. Tresiba long-acting double strength 84 units at night... This is an atypical instance of type 3c diabetes accompanied by post-surgical pancreatitis, biliary blockage, and a rapid onset of GAD-positive diabetes. Acute pancreatitis has been known to elevate GAD-antibody levels, which can result in insulin-dependent diabetes. The presented case is rare as GAD antibody levels are typically lower in autoimmune diabetes (less than 100 U/ML)."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Diabetes • Fatigue • Gastroenterology • Hepatology • Immunology • Insomnia • Metabolic Disorders • Pain • Pancreatitis • Pulmonary Disease • Respiratory Diseases • Sleep Disorder • Type 1 Diabetes Mellitus

A complex case of Type 1 DM with history of recurrent severe disabling hypoglycaemia treated with renal and pancreatic transplant. (ESPE-ESE 2025) - "He was only on a few units of insulin Tresiba and novorapid to control his blood sugar. This case highlights the importance of involving multidisciplinary teams including diabetologist, DSN, dietitian, transplant surgeon, psychiatrists, and nephrologist for coordinated effort in complex cases of hypoglycemia especially in type 1 DM patients. Those Patients who are not suitable for insulin therapy, considering pancreatic/pancreatic and renal transplants can be life-changing, especially those who are young and fit for surgery."

Clinical • Chronic Kidney Disease • Cognitive Disorders • Developmental Disorders • Diabetic Nephropathy • Hypoglycemia • Nephrology • Psychiatry • Renal Disease • Retinal Disorders • Severe Hypoglycemia • Transplantation • Type 1 Diabetes Mellitus

Type 2 Diabetes Mellitus in Teenagers – A Growing Concern for Armenia (ESPE-ESE 2025) - "Laboratory findings confirmed the diagnosis of T2DM: Fasting glucose: 28.7 mmol/L HbA1C: 11.0% C-peptide: 2.6 ng/mL Ketones: 3+ (indicating ketosis) Autoantibodies: Anti-GAD, IgG – 46.6 (>N) Anti-IA-2- 180.59 (>N) Anti-insulin, IgG – 10.13 (N) The patient’s treatment regimen included diet therapy (25 kcal/kg/day), insulin therapy (NovoRapid and Levemir), Metformin, and blood glucose monitoring 5-7 times per day. Early diagnosis and intervention, including lifestyle changes and pharmacological treatment, are essential to managing T2DM in teenagers and preventing long-term complications. Given the increasing prevalence of the condition in this age group, it is critical to recognize the early signs and implement appropriate strategies to address this growing public health issue."

Diabetes • Fatigue • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Afrezza® INHALE-1 Study in Pediatrics (clinicaltrials.gov) - P3 | N=319 | Completed | Sponsor: Mannkind Corporation | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Novo Nordisk Set to Stop Supply of a Key Diabetic Drug, Indian Patients Urge WHO, Govt to Intervene (The Wire) - "As many as 10 advocacy groups of diabetes patients of India shot a letter to the World Health Organisation (WHO) on May 5, urging it to urgently consider taking steps. This comes in the wake of Novo Nordisk, a Danish pharma multinational, deciding to phase out a key diabetic drug. Novo Nordisk is going to stop production of ‘human insulin’ in pen forms. Only the current available stock will be available to patients in India, and worldwide where it is mostly used....Novo Nordisk is phasing out the pen form of human insulin in next six months. And herein lies the problems for the patients, especially T1 ones. They have to take insulin in injectable form only....Novo Nordisk is going to continue the vial form of insulin."

Commercial • Diabetes

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Mark D. DeBoer, MD, MSc., MCR

New trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

RANDOMISED OPEN-LABEL CLINICAL TRIAL EXAMINING THE SAFETY AND EFFICACY OF THE ANDROID ARTIFICIAL PANCREAS SYSTEM WITH ADVANCED BOLUS-FREE FEATURES: THE CLOSE IT TRIAL (ATTD 2025) - "Full results will be available for presentation at ATTD 2025."

Clinical • Metastases • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

INFLUENCE OF DIETS DIFFERING IN MACRONUTRIENT COMPOSITION ON ENERGY METABOLISM DURING SUSTAINED, SUBMAXIMAL EXERCISE IN ADULTS WITH TYPE 1 DIABETES (ATTD 2025) - "This study profiled the metabolic responses to fasted submaximal cycling in adults with T1D following 7-days of adherence to diets differing in macronutrient composition.Methods In a randomised crossover design, 12 adults with T1D (n=4 female, age: 46±15 years, HbA1c: 55.9±7.8 mmol/mol) managed by non-automated insulin pump (n=9 Novorapid, n=3 Fiasp) consumed three diets over 7-days: HCLFLP (high carbohydrate (48%), low fat (33%), low protein (19%)), LCHFLP (low carbohydrate (19%), high fat (62%), low protein (19%)) and LCLFHP (low carbohydrate (19%), low fat (57%), high protein (24%)). Carbohydrate oxidation was greater in HCLFLP compared to LCHFLP (p=0.030), with concomitantly lower lipid oxidation (Table 1, p=0.030). Conclusions A 7-day low carbohydrate diet influenced fasted exercise metabolism with lower carbohydrate oxidation and circulating fatty acids despite similar glycaemic patterns in adults with T1D."

Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

CLOSE IT - Results from a randomized controlled fully closed loop trial (ATTD 2025) - "Twenty FCL arm participants will participate in a 4-week extension phase comparing NovoRapid® (insulin aspart) to Fiasp® (insulin aspart and niacinamide). Baseline data include median age 36 years (interquartile range, IQR 26-46), 48% female gender, median diabetes duration 19 years (IQR 11-30), 46% existing insulin pump users, median HbA1c 57mmol/mol (IQR 50-63). Conclusions Full results will be available for presentation at ATTD 2025."

Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (clinicaltrials.gov) - P2/3 | N=65 | Terminated | Sponsor: University of Minnesota | Completed ➔ Terminated

Trial termination • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Impact of Meal Insulin Bolus Timing and Bedtime Snacking on Continuous Glucose Monitoring-Derived Glycemic Metrics in Hospitalized Inpatients. (PubMed, Diabetes Technol Ther) - "Research Design and We conducted a post hoc analysis from the In-Fi study: a randomized controlled trial comparing Fiasp versus insulin aspart (Novolog) in inpatients with type 2 diabetes. Delayed mealtime insulin administration and bedtime snacking without insulin administration are significant causes of postprandial and overnight hyperglycemia in hospitalized inpatients. Adjustments in mealtime insulin protocols, attention to food intake, and the potential inpatient adoption of technology, such as CGM and automated insulin delivery systems, are needed to address this shortcoming in inpatient diabetes care."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

MIRE: Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes (clinicaltrials.gov) - P4 | N=38 | Terminated | Sponsor: University Hospital, Strasbourg, France | Trial completion date: Aug 2025 ➔ Jan 2025 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2025 ➔ Jan 2025; Difficulties of inclusion in this rare pathology

Trial completion date • Trial primary completion date • Trial termination • Cystic Fibrosis • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases